TrianglePUBLICATIONS · 33973307
FDA Approval Summary: Nivolumab Plus Ipilimumab for the Treatment of Patients with Hepatocellular Carcinoma Previously Treated with Sorafenib.
Open original source → · Download preserved record
Bibliographic metadata only. No full-text article or abstract is reproduced. Absence of a captured notice is not confirmation that a publication is clear of corrections or retractions.
- Journal
- Oncologist
- Publication date
- 2021 Sep
- First author
- Saung MT
Publication notices
- absence is not clearance
- true
- has correction metadata
- false
- has expression of concern metadata
- false
- has retraction in link
- false
- pubmed marks article retracted
- false
- pubmed marks retraction notice
- false
- relationships
Authors and identifiers
- name
- Saung MT
- type
- Author
- name
- Pelosof L
- type
- Author
- name
- Casak S
- type
- Author
- name
- Donoghue M
- type
- Author
- name
- Lemery S
- type
- Author
- name
- Yuan M
- type
- Author
- name
- Rodriguez L
- type
- Author
- name
- Schotland P
- type
- Author
- name
- Chuk M
- type
- Author
- name
- Davis G
- type
- Author
- name
- Goldberg KB
- type
- Author
- name
- Theoret MR
- type
- Author
Complete bibliographic record and source provenance
- authors
- name
- Saung MT
- type
- Author
- name
- Pelosof L
- type
- Author
- name
- Casak S
- type
- Author
- name
- Donoghue M
- type
- Author
- name
- Lemery S
- type
- Author
- name
- Yuan M
- type
- Author
- name
- Rodriguez L
- type
- Author
- name
- Schotland P
- type
- Author
- name
- Chuk M
- type
- Author
- name
- Davis G
- type
- Author
- name
- Goldberg KB
- type
- Author
- name
- Theoret MR
- type
- Author
- bibliography ids
- nci-bib-fa5f842c23f42d095885c0c9
- book metadata
- content sha256
- 9c718247a582f8a4e98211ff6999027dbb15edc4533163ff5c46ecfe510c48bc
- document type
- citation
- dois
- 10.1002/onco.13819
- electronic publication date
- display
- 2021 Jun 10
- precision
- day
- year
- 2021
- evidence scope
- bibliographic_metadata_only
- id
- pubmed:33973307
- immutable id
- pubmed:33973307@9c718247a582f8a4e98211ff6999027dbb15edc4533163ff5c46ecfe510c48bc
- journal
- abbreviation
- Oncologist
- issn electronic
- 1549-490X
- issn print
- 1083-7159
- issue
- 9
- name
- The oncologist
- nlm unique id
- 9607837
- pages
- 797-806
- volume
- 26
- languages
- eng
- notices
- absence is not clearance
- true
- has correction metadata
- false
- has expression of concern metadata
- false
- has retraction in link
- false
- pubmed marks article retracted
- false
- pubmed marks retraction notice
- false
- relationships
- outcomes validated
- false
- pmid
- 33973307
- provenance
- batch id
- 79f1021053e858d13ff3
- provider
- NCBI PubMed ESummary
- record sha256
- 57809cc7ddcc018c06eda14240af59338fa4134973ef9f4519faf2cecbae16b4
- response sha256
- 671d3d2962f73c698a1cb338d73222e2cc6cfdf61569f91b42612d5b59822e05
- retrieved at
- 2026-09-09T23:47:59.098265+00:00
- publication date
- display
- 2021 Sep
- precision
- month
- year
- 2021
- publication types
- Journal Article
- Review
- record status
- PubMed - indexed for MEDLINE
- schema version
- 1.0
- title
- FDA Approval Summary: Nivolumab Plus Ipilimumab for the Treatment of Patients with Hepatocellular Carcinoma Previously Treated with Sorafenib.
Preserved source evidence · Not medical advice